This book challenges professional and public misconceptions of schizophrenia as an illness with intractable symptoms and inexorable mental deterioration, educating clinicians and researchers on the effectiveness of treatment to change the course of or prevent the onset of illness. The authors illustrate such effectiveness through fifteen case studies examining psychosis in diverse clients. These case studies are divided into the three phases of the illness-prodromal/clinical high risk, first-episode, chronic, and treatment-refractory-with accompanying analyses of the causes, symptoms, interventions and treatments. By depicting patients at different clinical stages of the illness, with accompanying explanations of how they got to that point, what might have been done to avoid - or has been done to achieve - this outcome, the reader will gain an appreciation of the nature of the illness and for the therapeutic potential of currently available treatments. Readers will learn about the various clinical aspects of schizophrenia and treatment including diagnosis, prognosis, clinical presentation, suicide risk, cognitive deficits, stigma, medication management, and psychosocial interventions.

This book challenges professional and public misconceptions of schizophrenia as an illness with intractable symptoms and inexorable mental deterioration, educating clinicians and researchers on the effectiveness of treatment to change the course of or prevent the onset of illness. The authors illustrate such effectiveness through fifteen case studies examining psychosis in diverse clients. These case studies are divided into the three phases of the illness-prodromal/clinical high risk, first-episode, chronic, and treatment-refractory-with accompanying analyses of the causes, symptoms, interventions and treatments. By depicting patients at different clinical stages of the illness, with accompanying explanations of how they got to that point, what might have been done to avoid - or has been done to achieve - this outcome, the reader will gain an appreciation of the nature of the illness and for the therapeutic potential of currently available treatments. Readers will learn about the various clinical aspects of schizophrenia and treatment including diagnosis, prognosis, clinical presentation, suicide risk, cognitive deficits, stigma, medication management, and psychosocial interventions.

The new edition of The American Psychiatric Association Publishing Textbook of Schizophrenia plumbs the current state of knowledge about the disorder's origin, nature, and treatment in a comprehensive, authoritative, and thoroughly revised text. Schizophrenia is one of the leading causes of disability worldwide and remains among the most challenging and disheartening disorders confronting psychiatrists and other mental health care providers because of its profound effects on patient functioning, its onset just as young adults are launching their lives, and the limitations of current pharmacological treatments. Designed to bring the reader up to date on the latest research, this new edition represents a complete overhaul of the previous text, with a new structure, new chapters, and new contributors. Subjects such as genetics and neurobiology, distinguished by rapid advancements in knowledge, are explored in depth, as are new models of service delivery and psychosocial treatments that are making a significant difference in patients' lives. Foundational information on the epidemiology, etiology, and psychopathology of the illness is presented clearly and cogently, emphasizing research conducted over the last decade. Theories regarding the pathophysiological basis of the disorder, including genetic, molecular, and neurocircuitry models, are examined in detail. Other noteworthy topics include: * Cultural variations, examining how culture influences the presentation of schizophrenia from the perspective of the experts in cultural psychiatry who developed the DSM-5 Cultural Formulation Interview* Service delivery models, including assertive community treatment, critical time intervention, coordinated specialty care for early psychosis, and integrated dual diagnosis, informing clinicians about options for providing treatment to individuals with schizophrenia* Advances in the existing pharmacological treatments, including use of adjunctive medications and combinations of antipsychotics, which, in the absence of new drug therapies, is indispensable knowledge* A review of the promising field of neuromodulation* Evaluation and treatment of comorbidities, such as depression, obsessive-compulsive disorder, and substance use disorders, vital information because over half of people with schizophrenia have at least one co-occurring behavioral health disorder* Individual- and family-centered care, which presents the rationale and evidence for actively involving patients and family members in interventions and decision-making about treatments Designed for ease of use, The American Psychiatric Association Publishing Textbook of Schizophrenia furnishes evidence-based and cutting-edge knowledge for the next generation of students, trainees, and clinicians.

The body of knowledge that we have accumulated about the causes and nature of schizophrenia is prodigious, and the repertoire of evidence-based treatments is substantial and increasing. Comprehensive Care of Schizophrenia distills this corpus into the essential information that clinicians who care for persons with schizophrenia need to know. The second edition of the popular volume is thoroughly updated, offering new information on the advances in research and management since the first edition was published a decade ago. Chapters are streamlined to keep content as concise as possible, while key sections have been revised and expanded to include new information on drug therapy and advice on patient care. People with schizophrenia can suffer from multiple morbidities and disabilities, and thus may require a variety of treatments, both pharmacological and psychosocial. To cover the complex and growing field of schizophrenia management, renowned psychiatrists Jeffrey Lieberman and Robin Murray have recruited a distinguished group of researchers, practitioners and consumers of mental health care. This guide delves into to all aspects of the clinical management of schizophrenia for both the health care professional who treats patients as well as the researcher interested in the advances made in the field and their clinical application.

Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading.